Pancreatic cancer is a lethal disease and currently available therapies have significant
limitations. Pancreatic cancer is thus an ideal setting for the development of novel treatment …

Context Patients with resectable pancreatic cancer comprise a small subgroup of the overall
population with the disease from around 15 to 20%, with nearly all patients dying from their …

Survival data for pancreatic cancer are usually based on actuarial calculations and actual
long-term survival rates are rarely reported. Here we use population-level data from the …

Pancreaticoduodenectomy (PD) with the possible addition of neoadjuvant or adjuvant
therapy is the standard of care in the United States for adenocarcinoma originating in the …

The detailed biological functions of circular RNA (circRNA) are largely unexplored. Using
circRNA sequencing, we identified 169 differentially expressed circRNA in pancreatic ductal …

In this population-based retrospective study, we aimed to investigate the association
between age at diagnosis and prognosis of pancreatic cancer (PC) patients using data from …

Background Improved safety of pancreatic surgery has led to consideration of more
aggressive approaches, such as resection for primary pancreatic ductal adenocarcinoma …

Iron oxide nanoparticle-based hyperthermia is an emerging field in cancer treatment. The
hyperthermia is primarily achieved by two differing methods: magnetic fluid hyperthermia …

Pancreatic cancer (PaCa) is an aggressive malignancy with a high mortality rate and a poor
prognosis. To evaluate treatment outcomes of patients with pancreatic cancer over the past …

Pancreatic ductal adenocarcinoma (PDAC) represents one of the deadliest cancers in the
world. PDAC cells activate tumor-specific immune responses but simultaneously trigger a …